公开(公告)号：US20250059258A1

公开(公告)日：2025-02-20

申请号：US18721454

申请日：2022-12-23

Applicant: AVITIDE LLC

Inventor： Thomas Scanlon ,  Jonathan Belk ,  Kelley Kearns ,  Sarah Valentini

IPC: C07K16/00 ,  C07K1/22 ,  C07K14/00 ,  C07K17/08

Abstract: The present disclosure relates to the field of chromatography, and more specifically to novel affinity ligands and affinity agents which are suitable for use in isolation of antibody and antibody fragments that contain the heavy chain first constant region (CHI). The disclosure encompasses affinity ligands as such, chromatography separation matrices (affinity agents) comprising an affinity ligand according to the disclosure, and a process of isolating antibodies, especially IgGs, and CHI-containing antibody fragments thereof using an affinity ligand according to the disclosure. Methods of making the affinity ligands and separation matrices are also provided.

公开(公告)号：US20220213447A1

公开(公告)日：2022-07-07

申请号：US17613427

申请日：2020-05-22

Applicant: Avitide LLC

Inventor： William Scott Dodson ,  Brandon Kier ,  Brandon Coyle ,  Sarah Valentini ,  Thomas Scanlon ,  Warren Kett

IPC: C12N7/00 ,  C07K7/02 ,  C07K7/06 ,  C07K7/08 ,  B01D15/32 ,  B01D15/38

Abstract: Provided herein are affinity agents comprising ligands that specifically bind adeno-associated virus. The affinity agents are useful for binding, isolation, and/or purification of adeno-associated virus. Further disclosed are amino acid sequences of binding motifs or polypeptides comprised by the ligands, and associated modifications of the binding motifs and/or polypeptides, as well as a method of making the affinity agents.

公开(公告)号：US20230391829A1

公开(公告)日：2023-12-07

申请号：US18031833

申请日：2021-10-13

Applicant: Avitide LLC

Inventor： Sarmistha Bhattacharya ,  Brandon Coyle ,  Sarah Valentini ,  Kelley Kearns ,  Thomas Scanlon ,  William Wellborn ,  Warren Kett

IPC: C07K14/00 ,  C07K1/22 ,  B01D15/38

CPC classification number: C07K14/001 ,  C07K2319/21 ,  B01D15/3804 ,  C07K1/22

Abstract: Provided herein are affinity ligands that specifically interact with AAV8 capsid and/or AAV8 variant capsid, affinity agents comprising the affinity ligands, and methods of their use for binding, isolation, and/or purification of AAV8 and variants thereof.